| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 34.18 | 15.3% |
| Total Income | 36.45 | 17.4% |
| Expenditure | 30.59 | 23.9% |
| PBT | 5.87 | 48.3% |
| Net Profit | 5.02 | 63.4% |
| OPM | 14.84% | 10.22pp |
| NPM | 13.76% | 6.81pp |
| EPS | 0.22 | 69.2% |
Gennex Laboratories Ltd. Reports Q1 2025 Financial Results with 40.33% YoY Revenue Growth
14 Aug 2025 · 14 Aug 2025, 05:37 pm
Summary
Gennex Laboratories Ltd. has reported its financial results for Q1 2025. The company has seen a significant revenue growth of 40.33% YoY. The financial statements were reviewed by the Audit Committee and approved by the Board of Directors on 14.08.2025. The company operates in the 'Bulk Drugs,Biotech Products and Intermediates' segment. The quarterly unaudited financial results are available on the company's website and the BSE website.
Key Highlights
- 1
Q1 2025 revenue growth of 40.33% YoY
- 2
Operates in the 'Bulk Drugs,Biotech Products and Intermediates' segment
- 3
Financial statements reviewed by the Audit Committee on 14.08.2025
- 4
Quarterly unaudited financial results available on the company's website and the BSE website
Management Comments
ARIHANT nares BAID
The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 14.08.2025 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
Informational and educational content only. Not investment advice.